Visual impairment is a global epidemic affecting millions 

of individuals currently. A large portion of these individuals 

suffer from chronic age-related macular degeneration 

(AMD), characterized by progressive neovascularization 

and vascular leakage near the central region (macula) of 

the retina. Current treatments for AMD, including laser photocoagulation, photodynamic therapy, and surgery, 

only benefit patients in the advanced stages and temporarily 

alleviate the progression of the disease.  The need for more

effective therapies has fostered the development of anti-

vascular endothelial growth factor (VEGF) treatments. 

Although anti-proliferative agents have shown improved

efficacy, repeated injections with 6-8 week intervals are

often required to maintain therapeutic efficacy of these 

drugs, leading to inconvenience, higher cost and risk of 

injection-related complications such as endophthalmitis

and retinal detachment. Regarding treatment, retinal 

specialists have identified the 2 greatest unmet needs as 

being reduced treatment burden and to develop longer 

acting/sustained released drugs.  Spinnaker's controlled

release drug delivery system addresses both of these 

unmet needs.  

• Improved drug delivery to site of action - back of the eye
• Reduced systemic/off-target toxicity
• Prolong drug release and protect therapeutics
• Provide continuous drug release for >4 months
• Advantages in treatment duration and dosing
• Reduces number of injections and risk of infection
• Improved formulation for optimal administration
• Solution that allows reproducible, high dose drug delivery
• Animal safety studies demonstrated non-toxic formulation